These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 9156935)

  • 21. [Study of the blood platelets in chronic dialyzed patients before and after hemodialysis. Comparison with a group of patients with grave chronic uremia treated with occasional dialysis].
    Praga C; Brancaccio D; Pogliani E; Della Grazia M
    Minerva Nefrol; 1968; 15(5):322-6. PubMed ID: 5743459
    [No Abstract]   [Full Text] [Related]  

  • 22. Removal of uremic toxins and regeneration of hemofiltrate by a selective dual hemofiltration artificial kidney (SEDUFARK) system.
    Jørstad S; Smeby LC; Widerøe TE; Berg KJ
    Clin Nephrol; 1980 Feb; 13(2):85-92. PubMed ID: 6988123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Middle molecular weight substances and uremic polyneuropathy.
    Dukanović L; Petrović J; Potić J
    Acta Med Iugosl; 1990; 44(2):117-28. PubMed ID: 2162129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parathyroid hormone immunoreactivity in the plasma filtrate of uremic patients.
    Tsutsumi M; Fukase M; Fujita T; Fujita K; Inoue S; Shin J
    Miner Electrolyte Metab; 1982 Mar; 7(3):146-50. PubMed ID: 7169980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro cytotoxic properties of plasma fractions from uremic patients.
    Delaporte C; Gros F; Jonsson C; Bergström J
    Artif Organs; 1981; 4 Suppl():68-70. PubMed ID: 7295099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100 ): influence of hematocrit elevation.
    Escolar G; Cases A; Viñas M; Pino M; Calls J; Cirera I; Ordinas A
    Haematologica; 1999 Jul; 84(7):614-9. PubMed ID: 10406903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uremic ultrafiltrate inhibits platelet-activating factor synthesis.
    Wratten ML; Tetta C; De Smet R; Neri R; Sereni L; Camussi G; Vanholder R
    Blood Purif; 1999; 17(2-3):134-41. PubMed ID: 10449871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Medium molecular weight uremic toxins and endogenous polyamines. Behavior of polymorphonuclear leukocyte chemotaxis with respect to chromatographic peaks of dialysate and standard polyamines].
    Stabellini G; Spisani S; Fiocchi O; Stabellini N; Carletti R; Altobelli A; Farinelli A
    Boll Soc Ital Biol Sper; 1982 Nov; 58(21):1418-24. PubMed ID: 7159534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients.
    Moia M; Graziani G; Tenconi PM; Martinelli I; Ponticelli C
    Ann Ital Med Int; 1997; 12(2):67-71. PubMed ID: 9284597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MLC-blocking factors in uremic sera.
    Fehrman I; Ringdén O; Bergström J
    Clin Nephrol; 1980 Oct; 14(4):183-9. PubMed ID: 7000408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [High molecular substances in relation to disorders of erythropoiesis in patients in the terminal stage of chronic renal failure].
    Gudim WI; Sukiasowa TG; Iwanowa WS; Gorbunowa NA; Kosinez GI
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(6):834-44. PubMed ID: 2453413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet function in patients on maintenance hemodialysis: depressed or enhanced?
    Remuzzi G; Benigni A; Dodesini P; Schieppati A; Gotti E; Livio M; Mecca G; Donati B; de Gaetano G
    Clin Nephrol; 1982 Feb; 17(2):60-3. PubMed ID: 7067167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uremic middle molecules: analytical study of middle molecular weight fractions subpeak b4-2.
    Le Moel G; Strecker G; Cueille G; Boudet J; Man NK; Galli A; Agneray J
    Artif Organs; 1981; 4 Suppl():17-21. PubMed ID: 7295087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Technical aspects on middle molecules: separation, isolation, and identification.
    Cueille G; Man NK; Sausse A; Farges JP; Funck-Brentano JL
    Artif Organs; 1981; 4 Suppl():8-12. PubMed ID: 7295100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A compound inhibiting platelet aggregation in hemofiltrate from uremic patients.
    Tatsumi Y; Tatsumi J; Kojima K; Tatsumi N; Okuda K; Iritani Y; Ikeuchi H; Yamagami S
    Osaka City Med J; 1984 Jun; 30(1):31-8. PubMed ID: 6514335
    [No Abstract]   [Full Text] [Related]  

  • 36. Identification of renin inhibitors in normal and uremic plasma.
    Kotchen TA; Talwalkar RT; Kaul K
    J Lab Clin Med; 1985 Mar; 105(3):286-93. PubMed ID: 3882863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The calcium-phosphorus balance and parathormone behavior in 7 patients treated with integral hemofiltration].
    Civati G; Guastoni C; Perego A; Galato R; Brando B; Grillo C; Surian M; Colussi G; Teatini U; Minetti L
    Minerva Nefrol; 1981; 28(2):171-4. PubMed ID: 7290521
    [No Abstract]   [Full Text] [Related]  

  • 38. [Changes in serum profile of medium molecules in patients treated with dialysis for various lengths of time].
    Manari A; Buzio C; Calderini C; David S; Montagna G; Quaretti P; Gröf J; Migone L
    Minerva Nefrol; 1982; 29(2):93-100. PubMed ID: 7133545
    [No Abstract]   [Full Text] [Related]  

  • 39. Low molecule and middle molecule metabolites with haemodynamic activity in the ultrafiltrate from uraemic patients (author's transl).
    Pogglitsch H; Petek W; Waller J; Stübchen-Kirchner H
    Wien Klin Wochenschr; 1977 Dec; 89(24):812-9. PubMed ID: 595605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of middle molecules in uremic patients.
    Wu ZG; Cai ZH; Lu ZN; Liao LT; Zhu SQ
    Chin Med J (Engl); 1985 Feb; 98(2):115-20. PubMed ID: 3922688
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.